Journal of endocrinological investigation · 2026
Predictors of prolonged hypogonadism in men with prolactinomas despite biochemical remission: the role of baseline luteinizing hormone.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gozukan Gokberk, Tunc Topuz Busra, Tufan Ceren, Saygili Emre Sedar, Karakilic Ersen
Аннотация
PURPOSE: Recovery of gonadal function in men with prolactinomas following dopamine agonist therapy is variable, and predictors of hypogonadism remain unclear. We aimed to identify predictors of prolonged hypogonadotropic hypogonadism (HH) in men achieving normoprolactinemia during cabergoline therapy.
METHODS: In this retrospective cohort study, 71 male patients with prolactinomas were screened; 51 were included in the baseline analysis, and 39 patients achieving biochemical remission with adequate follow-up were included in the longitudinal outcome analysis. Prolonged hypogonadism was defined as persistence of low testosterone levels for > 12 months after prolactin normalization. Predictors were assessed using group comparisons, univariate logistic regression, and ROC curve analysis.
RESULTS: Prolonged HH was observed in 25.6% of patients despite prolactin normalization. Baseline LH demonstrated high discriminative performance (AUC: 0.886), with a cut-off ≤ 2.47 IU/L yielding high specificity (93.1%). Baseline total testosterone (AUC: 0.829, ≤ 1.95 ng/mL [6.8 nmol/L]), prolactin (AUC: 0.802, ≥ 141.9 ng/mL), and tumor diameter (AUC: 0.780, ≥ 7.6 mm) were also associated with prolonged HH. Longitudinal trajectories demonstrated increases in LH and testosterone during the first 12 months, followed by a plateau phase. However, testosterone recovery remained incomplete in the prolonged HH group, although delayed normalization was observed during follow-up.
CONCLUSION: Baseline LH was strongly associated with prolonged hypogonadism in prolactinomas and may serve as a marker for early risk stratification. Most hormonal recovery occurred within the first 12 months after prolactin normalization, supporting the clinical relevance of this time point. Baseline hormonal and structural parameters may help guide follow-up and testosterone replacement decisions.
METHODS: In this retrospective cohort study, 71 male patients with prolactinomas were screened; 51 were included in the baseline analysis, and 39 patients achieving biochemical remission with adequate follow-up were included in the longitudinal outcome analysis. Prolonged hypogonadism was defined as persistence of low testosterone levels for > 12 months after prolactin normalization. Predictors were assessed using group comparisons, univariate logistic regression, and ROC curve analysis.
RESULTS: Prolonged HH was observed in 25.6% of patients despite prolactin normalization. Baseline LH demonstrated high discriminative performance (AUC: 0.886), with a cut-off ≤ 2.47 IU/L yielding high specificity (93.1%). Baseline total testosterone (AUC: 0.829, ≤ 1.95 ng/mL [6.8 nmol/L]), prolactin (AUC: 0.802, ≥ 141.9 ng/mL), and tumor diameter (AUC: 0.780, ≥ 7.6 mm) were also associated with prolonged HH. Longitudinal trajectories demonstrated increases in LH and testosterone during the first 12 months, followed by a plateau phase. However, testosterone recovery remained incomplete in the prolonged HH group, although delayed normalization was observed during follow-up.
CONCLUSION: Baseline LH was strongly associated with prolonged hypogonadism in prolactinomas and may serve as a marker for early risk stratification. Most hormonal recovery occurred within the first 12 months after prolactin normalization, supporting the clinical relevance of this time point. Baseline hormonal and structural parameters may help guide follow-up and testosterone replacement decisions.